World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 4, Number 4-5, October 2013, pages 179-187


Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma

Figures

Figure 1.
Figure 1. Kaplan-Meier Overall Survival Curves according to KRAS gene status (mutated and wild-type), P-value = 0.407. Legend: K-RAS mutated: 1; K-RAS wild-type: 2.
Figure 2.
Figure 2. Kaplan-Meier Overall Survival Curves of patients with K-RAS mutated according to mutation in codons 12 and 13, P-value = 0.651. Legend: K-RAS mutated codon 12: 1; K-RAS mutated codon 13: 2.

Tables

Table 1. Distribution of K-RAS Mutation Status and Clinical-Pathological Tumor Features in Colorectal Cancer Patients
 
Clinical-pathological featuresTotal (n = 65)K-RAS wild-type (n = 33)K-RAS mutated (n = 32)P-value
ECOG: Eastern Cooperative Oncology Group; LNR: lymph node ratio.
Gender0.195
  Male281216
  Female372116
Age0.046
  > 65 years443014
  < 65 years21318
ECOG0.495
  0381721
  1251510
  2211
Histological type0.256
  Adenocarcinoma502723
  Mucinous1569
Cell differentiation0.221
  well492722
  intermediate16610
LNR > 0.16(60)0.371
  Yes341717
  No261115
Lung metastasis0.531
  Yes341618
  No311714
Liver metastasis0.663
  Yes432122
  No221210
Synchronous metastasis0.051
  Yes351421
  No301911
Primary tumor site0.914
  Colon281414
  Rectum371918
Obstructive and/or perforated acute abdomen0.273
  Yes1174
  No542628
Staging0.074
  II13103
  III1798
  IV351421
Recurrence0.067
  Yes563125
  No927

 

Table 2. Distribution of K-RAS Mutation Types in Colorectal Cancer Patients, Point Mutations and Amino Acids Exchanged
 
CodonMissense mutationAmino acid Wild-typeAmino acid mutatedn = 32 (%)
n: number of patients; G: nucleotide glycine; A: nucleotide alanine; T: nucleotide thymine; C: nucleotide cytosine; Gly: nucleotide glycine; Asp: nucleotide aspartate; Val: nucleotide valine; Ala: nucleotide alanine; Ser: nucleotide serine; Cys: nucleotide cisteine.
12 (n = 24)G-AGGT (Gly)GAT (Asp)11 (34.37%)
G-TGGT (Gly)GTT (Val)6 (18.75%)
G-TGGT (Gly)TGT (Cys)4 (12.5%)
G-AGGT (Gly)AGT (Ser)2 (6.25%)
G-CGGT (Gly)GCT (Ala)1 (3.125%)
13 (n = 8)G-AGGC (Gly)GAC (Asp)7 (21.87%)
G-TGGC (Gly)GTT (Val)1 (3.125%)

 

Table 3. Binary Logistic Regression Analysis and Distribution of the Probabilities of Occurrence of Liver and Lung Metastases According to Primary Site and Tumor KRAS Mutation Status
 
Kras wild-typeKras mutatedP-value
P: probability.
Liver metastasiscolonP: 0.766581P: 0.8048480.160
rectumP: 0.540414P: 0.596230
Lung metastasiscolonP: 0.424453P: 0.5041180.579
rectumP: 0.529350P: 0.607908

 

Table 4. Multivariate Analysis of Clinical-Pathological Features Associated With Prognostic Value in Colorectal Cancer Patients
 
CharacteristicsRelative RiskCI (Confidence interval) 95%P-value
K-RAS mutation-1.76-0.9537 - 0.05010.078
Cell differentiation,-0.79-0.8236 - 0.34920.428
Gender-0.74-0.6267 - 0.28290.459
Age0.47-0.0118 - 0.01910.642
Primary tumor site1.16-0.1708 - 0.66790.245
Lymph node involvement-1.62-0.8142 - 0.07630.104
Liver metastasis2.650.2427 - 1.62570.008
Lung metastasis-1.560.7462 - 0.08590.120
Synchronous metastasis2.920.2961 - 1.49980.003
Histological type-0.70-0.6845 - 0.32480.485